Document ID: FDA-2020-N-0001-0003
Agency: fda
Document Type: Notice
Title: March 10 Through April 30, 2020, Public Meetings; Postponement,
Cancellation, or Remote Only
Posted Date: 2020-03-19T04:00Z

[Federal Register Volume 85, Number 54 (Thursday, March 19, 2020)]
[Notices]
[Pages 15789-15790]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-05743]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2020-N-0001, FDA-2020-N-0255, FDA-2020-N-0256, FDA-
2020-N-0259, FDA-2018-N-4337]

March 10 Through April 30, 2020, Public Meetings; Postponement, 
Cancellation, or Remote Only

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is announcing that certain 
meetings involving the Center for Drug Evaluation and Research (CDER) 
from March 10 through April 30, 2020, are postponed, cancelled, or 
modified to take place remotely.

DATES: For dates that have been either postponed or cancelled, see 
table 1 in the SUPPLEMENTARY INFORMATION section.

FOR FURTHER INFORMATION CONTACT: Kim Thomas, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 51, Rm. 6282, Silver Spring, MD 20993-0002, 301-796-2357, 
Kimberly.K.Thomas@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Certain public meetings involving CDER from 
March 10 through April 30, 2020, are postponed, cancelled, or modified 
to take place remotely due to extenuating circumstances. The meetings 
that are postponed or canceled as part of this notice are listed in 
table 1. If a meeting is rescheduled, information about the rescheduled 
meeting will be provided in the future. The meeting that will no longer 
take place in person and instead take place by webcast only as part of 
this notice is listed in table 2.\1\
---------------------------------------------------------------------------

    \1\ Up-to-date information about public meetings involving CDER 
is available on the internet at https://www.fda.gov/drugs/news-events-human-drugs/meetings-conferences-workshops-drugs.

[[Page 15790]]

                                  Table 1--CDER Meetings Postponed or Cancelled
----------------------------------------------------------------------------------------------------------------
                                                                                                Federal Register
       Meeting type             Meeting title        Original meeting date       Docket No.          citation
----------------------------------------------------------------------------------------------------------------
Public Meeting............  Patient-Focused Drug   Mar. 10, 2020............  FDA-2020-N-0259.  85 FR 8877, Feb.
                             Development for                                                     18, 2020.
                             Stimulant Use
                             Disorder.
Public Meeting............  Patient-Focused Drug   Mar. 30, 2020............  FDA-2020-N-0255.  85 FR 8004, Feb.
                             Development for                                                     12, 2020.
                             Vitiligo.
Public Meeting............  Scientific and         Apr. 16, 2020............  FDA-2020-N-0001.  85 FR 14207,
                             Ethical                                                             Mar. 11, 2020.
                             Considerations for
                             the Inclusion of
                             Pregnant Women in
                             Clinical Trials.
Public Meeting............  Prescription Drug      Apr. 22, 2020............  FDA-2018-N-4337.  85 FR 6547, Feb.
                             User Fee Act of                                                     5, 2020.
                             2017; Electronic
                             Submissions and Data
                             Standards.
----------------------------------------------------------------------------------------------------------------

                                                           Table 2--CDER Meeting Held Remotely
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                             Federal Register
        Meeting type                Meeting title           Original meeting date          Docket No.            citation          Remote information
--------------------------------------------------------------------------------------------------------------------------------------------------------
Public Meeting..............  United States Food and    Apr. 3, 2020................  FDA-2020-N-0256....  85 FR 13659, Mar.    https://www.fda.gov/
                               Drug Administration and                                                      9, 2020.             drugs/news-events-human-
                               Health Canada Joint                                                                               drugs/health-canada-and-
                               Regional Consultation                                                                             fda-joint-public-
                               on the International                                                                              consultation-
                               Council for                                                                                       international-council-
                               Harmonisation of                                                                                  harmonisation-technical-
                               Technical Requirements                                                                            0.
                               for Pharmaceuticals for
                               Human Use.
--------------------------------------------------------------------------------------------------------------------------------------------------------

    Dated: March 16, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-05743 Filed 3-18-20; 8:45 am]
 BILLING CODE 4164-01-P